Matthew T. Drake, MD, Ph.D, is a board certified Endocrinologist at HSS and Chief of the Endocrinology and Metabolic Bone Disease Services where he provides care to patients with metabolic bone diseases, rare bone diseases, and cancers that affect the skeleton. He formerly served as Consultant and Associate Professor of Medicine at the Mayo Clinic in Rochester, Minnesota, including as Chair of the Mayo Clinic Endocrinology Metabolic Bone Disease Group during the decade prior to his move to HSS in January 2025.
After receiving his AB degree from Harvard College, where he graduated magna cum laude, Dr. Drake completed his MD and PhD degrees in the Medical Scientist Training Program at Washington University in St. Louis. His clinical training in Internal Medicine was performed at Duke University Medical Center in Durham, North Carolina. He completed his Endocrinology fellowship training at Mayo Clinic in the Clinician-Investigator Pathway, joining the Mayo Clinic staff in 2007.
Dr. Drake has performed basic, translational, and clinical research under NIH-sponsored grants and has published over 130 articles in a variety of scientific journals including the Journal of Bone and Mineral Research, Bone, Nature Medicine, Lancet Diabetes and Endocrinology, JAMA, the Journal of Clinical Investigation, the Journal of Clinical Endocrinology and Metabolism, Osteoporosis International, Lancet Oncology, and Blood. His research focuses on understanding the mechanisms underlying age-associated bone loss and the skeletal microarchitectural changes that accompany this condition, as well as the basis by which monoclonal gammopathies (monoclonal gammopathy of undetermined significance/MGUS and multiple myeloma) induce bone loss and fractures.
Dr. Drake has received numerous awards, including the American Society for Bone and Mineral Research (ASBMR) Young Investigator Award and the Mayo Clinic Department of Medicine New Investigator Award. He has previously served, or is currently serving on, the editorial boards of the Journal of Bone and Mineral Research (JBMR), JBMR Plus,
the Journal of Clinical Endocrinology and Metabolism, and Mayo Clinic Proceedings. He currently serves as a member of the Scientific Advisory Boards for the Soft Bones Foundation, the Fibrous Dysplasia Foundation, and the Rare Bone Disease Network, and previously served on the Orthopedic Research Society (ORS) and Advances in Mineral Metabolism (AIMM) meeting development committees. He also serves a member of the American Board of Internal Medicine Endocrinology Examination Committee.
Dr. Drake has previously served as Chair of the American Society for Bone and Mineral Research (ASBMR) Professional Practice Committee and as a member of the ASBMR Ethics Committee and is a current member of the ASBMR Council. He previously served on the Endocrine Society Annual Meeting Steering Committee. He previously served as a member of the United States Food and Drug Administration (FDA) Bone, Reproductive, and Urologic Drugs Advisory Committee, is a current member of the FDA Endocrine and Metabolic Drugs Advisory Committee, and has served on numerous NIH, US government, foundation, and international grant review committees. At Mayo Clinic, Dr. Drake also served on the Institutional Review Board (IRB) overseeing human studies research, including as IRB Chair for the six years preceding his arrival at HSS.
Internal Medicine, Endocrinology, Metabolic Bone
Osteoporosis and Metabolic Bone Health
This provider is currently in the process of joining the networks of many commercial insurance plans and should show as a participating provider soon.
If your insurance is not listed, please call our office if you have questions regarding your insurance coverage. If you have out-of-network benefits, then your insurance may reimburse you for a portion of your office visit. We will work with you and your insurance to minimize your out-of-pocket costs. Financial assistance may be available for patients in need.
Chief, Endocrinology and Metabolic Bone Disease Services, Hospital for Special Surgery
Attending Physician, Hospital for Special Surgery
American Society for Bone and Mineral Research, Member 2004 - Present
American Society for Bone and Mineral Research Abstract Selection Committee, Reviewer 2010 - 2018
American Society for Bone and Mineral Research Professional Practice Committee, Member 2011 - 2014
American Society for Bone and Mineral Research Task Force on Managing Osteoporosis Patients after Long-Term Bisphosphonate Treatment, Member 2013 - 2016
American Society for Bone and Mineral Research Task Force on Cell Based Therapies, Independent Content Reviewer 2014 - 2020
American Society for Bone and Mineral Research, Rare Bone Disease Working Group, Chair 2016 - 2017
American Society for Bone and Mineral Research Harold Frost Young Investigator Award Review Committee, Chair 2017
American Society for Bone and Mineral Research Rising Star Awards Scientific Review Committee, Member 2018 - 2020
American Society for Bone and Mineral Research Ethics Advisory Committee, Member 2018 - 2019
American Society for Bone and Mineral Research Annual Meeting Program Advisory Committee, Member 2019 - Present
American Society for Bone and Mineral Research Professional Practice Committee, Chair 2019-2023
American Society for Bone and Mineral Research, Member Council 2024 - Present
American Board of Internal Medicine Endocrine Examination Committee, Member 2018 - Present
American Society of Hematology, Member 2009 - Present
Endocrine Society, Member 2004 - Present
Endocrine Society Facts and Figures Bone Working Group, Member 2014 - 2015
Endocrine Society Annual Meeting Steering Committee Bone and Mineral Group, Team Leader 2016-2019
Endocrine Society Clinical Practice Guideline Committee for Hypercalcemia of Malignancy, Co-chair 2018-2023
Endocrine Society Task Force on Osteoporosis in Men, Member 2011 - 2012
FDA Bone, Reproductive, and Urologic Drugs Advisory Committee, Member 2015 - 2021
FDA Endocrine and Metabolic Drugs Advisory Committee, Member 2022 - Present
International Myeloma Society, Member 2010 - Present
International Myeloma Working Group, Member 2010 - Present
Orthopedic Research Society Advisory Board, Member 2017-2020
Rare Bone Disease Alliance, Member 2018 - Present
American Board of Internal Medicine Endocrinology, Diabetes and Metabolism 2007 - Present
American Board of Internal Medicine Internal Medicine 2004 - 2014
New Investigator Award - Mayo Clinic Department of Medicine 2010
Young Investigator Award - American Society for Bone and Mineral Research 2009
Medical Specialties 2001 - 2007
Clinical Investigator Pathway - Multi-Specialty MOC Portfolio Program: Clinical Investigator Pathway, American Board of Physician Scientist Training Program - Washington University School of Medicine 2001
Medical Scientist Training Program - Washington University School of Medicine 1994 - 2001
Fellowship - Foundation Jean Dausset - CEPH 1994
Summa Cum Laude Undergraduate Thesis - Harvard College 1993
Magna Cum Laude, A.B. in Biology - Harvard College 1993
John Harvard Scholar - Harvard College 1989-1993
Medical: Washington University - MD/PhD, Medicine Molecular and Cell Biology, 2001
Internship: Duke University Medical Center - Internship, Internal Medicine, 2002
Residency: Duke University Medical Center - Residency, Internal Medicine, 2004
Fellowship: Duke University Medical Center - Endocrinology, Diabetes, and Metabolism, 2006
Mayo Clinic College of Medicine - Endocrinology, Diabetes, and Metabolism, 2007
English
For all publications, please see the PubMed listing.
The Long and Winding Road to Improving Bone Mineral Density Testing and Reporting. Kennel KA, Drake MT. Mayo Clin Proc. 2024 Jul;99(7):1027-1029. PMID: 38960491
Optimising zoledronate treatment holiday duration without loss of fracture prevention. Drake MT. Lancet Diabetes Endocrinol. 2024 Apr;12(4):217-219. PMID: 38452785
Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline. El-Hajj Fuleihan G, Clines GA, Hu MI, Marcocci C, Murad MH, Piggott T, Van Poznak C, Wu JY, Drake MT. J Clin Endocrinol Metab. 2023 Feb 15;108(3):507-528. PMID: 36545746
Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group. Terpos E, Zamagni E, Lentzsch S, Drake MT, García-Sanz R, Abildgaard N, Ntanasis-Stathopoulos I, Schjesvold F, de la Rubia J, Kyriakou C, Hillengass J, Zweegman S, Cavo M, Moreau P, San- Miguel J, Dimopoulos MA, Munshi N, Durie BGM, Raje N; Bone Working Group of the International Myeloma Working Group. Lancet Oncol. 2021 Mar;22(3):e119-e130. PMID: 33545067
Update on Approved Osteoporosis Therapies Including Combination and Sequential Use of Agents. Saul D, Drake MT. Endocrinol Metab Clin North Am. 2021 Jun;50(2):179-191. PMID: 34023037
Optimizing DXA to Assess Skeletal Health: Key Concepts for Clinicians. Kennel KA, Sfeir JG, Drake MT. J Clin Endocrinol Metab. 2020 Dec 1;105(12). PMID: 32894765
Defining Very High Fracture Risk: Is FRAX Fit for Purpose? Compston JE, Drake MT. J Bone Miner Res. 2020 Aug;35(8):1399-1403. PMID: 32696997
Determinants of Bone Material Strength and Cortical Porosity in Patients with Type 2 Diabetes Mellitus. Samakkarnthai P, Sfeir JG, Atkinson EJ, Achenbach SJ, Wennberg PW, Dyck PJ, Tweed AJ, Volkman TL, Amin S, Farr JN, Vella A, Drake MT, Khosla S.
J Clin Endocrinol Metab. 2020 Oct 1;105(10). PMID: 32556277
Use of trabecular bone score for risk stratification of patients with monoclonal gammopathy of undetermined significance. Sfeir JG, Pena Guzman TD, Bedatsova L, Broski SM, Drake MT. Bone. 2020 Aug;137:115394. PMID: 32360588
Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research. Adler RA, El-Hajj Fuleihan G, Bauer DC, Camacho PM, Clarke BL, Clines GA, Compston JE, Drake MT, Edwards BJ, Favus MJ, Greenspan SL, McKinney R Jr, Pignolo RJ, Sellmeyer DE. J Bone Miner Res. 2016 Jan;31(1):16-35. PMID: 26350171
HSS has a long history of supporting appropriate relationships with industry because they advance HSS's mission to provide the highest quality patient care, improve patient mobility, and enhance the quality of life for all, and to advance the science of orthopedic surgery, rheumatology, and their related disciplines through research and education.
As of February 26, 2025, Dr. Drake reported no relationships with the healthcare industry.
HSS and its physicians make this information available to patients and the public, thus creating a transparent environment for those who are interested in this information. Further, the HSS Conflicts of Interest and Commitment Policy prohibits physicians from collecting royalties on products they develop that are used on patients at HSS.
